The decline of shares in the pharmaceutical sector can be explained by the pressure on prices of existing drugs and the difficulty in finding new molecules for the therapies of tomorrow. However, the decline of certain stocks is exaggerated. In Switzerland, while Novartis has problems of its own, one must recognize that Roche is doing better,
This spring, the markets were in full panic mode and the mining stocks were at their bottom. Chinese overcapacities, decline in global demand, balance sheets with too much debt, all the arguments were good for the banks to recommend to their clients to sell their shares in this sector.